Dr. Srivastava is currently a University Distinguished Professor and Chairman of the Department of Immunotherapeutics and Biotechnology at Texas Tech University Health Sciences Center (TTUHSC), Abilene, Texas, specializing in Cancer Biology, Chemoprevention and Cancer Therapeutics. Dr. Srivastava also holds James A ‘Buddy’ Davidson Endowed Professorship in Pharmacology and Oncology. In addition, he served as an Associate Dean for Research for 6 years, and Associate Dean for Graduate Program in Pharmaceutical Sciences and Biotechnology for 4 years at TTUHSC. He was instrumental in bringing the Ph.D. program to Abilene campus. Prior to his arrival at TTUHSC in 2007, Dr. Srivastava served as an Assistant Professor in the Department of Pharmacology, University of Pittsburgh School of Medicine and was a full member of the University of Pittsburgh Cancer Institute at Hillman Cancer Center. He did his post-doctoral studies from the University of Texas Medical Branch at Galveston, Texas. Dr. Srivastava’s current research is focused on understanding the mechanism of resistance to chemotherapeutic drugs, immunotherapy and repurposing non-cancer drugs for therapy of melanoma, brain cancer, breast cancer, pancreatic cancer, osteosarcoma, and ovarian cancer, and is funded by grants from the National Cancer Institute, NIH. He has authored more than 170 research articles, several book chapters, Editor of three books, and has an H-Index 61. He also holds several patents and received numerous awards. He was named in Stanford University’s list for the World’s Top 2% Scientists for the year 2020 & 2021. He recently received the honor to be elected as the Fellow of American Association for the Advancement of Science (AAAS), a very prestigious scientific organization. Dr. Srivastava is in the editorial board of several prestigious journals and is the member of societies including AACR, SOT, AAAS and AAPS. He serves in the grant review panels of National Institute of Health (NIH), Department of Defense and other agencies. His research work has been featured by various news agencies.

Languages

Hindi

Interests

Biochemistry
Bone cancer
Breast health/cancer
Cancer
Cell biology
Colorectal cancer
Dermatology
Gastroenterology
Gynecology
Lung cancer
Molecular genetics
Oncology
Ovarian cancer
Pharmacology
Research
Skin cancer

Pharmacy Research Interests

Breast Cancer
DNA
Gli1
Gli2
LC-MS/MS, LC-UV/VIS, LC-ECD, UPLC-MS/MS
Mcl-1 inhibitors
NFkB
Oriental herbal extract
Ovarian Cancer
Pancreatic Cancer
STAT-3
T Cells
Triphala
anti-psychotic drugs for cancer treatment
apoptosis
benzylisothiocyanate (BITC)
biochemistry
blood-brain barrier (BBB)
brain drug transport
brain tumor
cancer
cancer biology
cancer chemotherapy
cancer development
cancer immunotherapy
capsaicin
carcinogenesis
cell cycle regulation
cell signaling
chemo-prevention
chemotherapy
cucurbitacin B
curcumin
diindolylmethane (DIM)
drug delivery
drug delivery systems
drug development
drug discovery
drug efficacy
drug formulation
drug toxicity
drug transport
endothelial cells
experimental therapeutics
gel electrophoresis
gene regulation
gene silencing
genetics
glioblastoma (GBM)
hematology/oncology
hypoxia
immunotherapy
intracardiac tumor model
intracranial tumor model
invitro
invivo
liposomes
marine natural products
metastasis
microenvironment
molecular biology
molecular pathology
nanoparticles
natural products
novel immunotherapy
oncogene
oncology
orthotopic tumor model
penfluridol
pharmacokinetic studies
pharmacokinetics
pharmacology
phenethylisothiocyanate (PEITC)
phytochemistry
piparin
piperlartine
piperlongumine
preclinical pharmacology
redox signaling
signal transduction
stem cell
temozolomide
transporter
tumor immunology
tumor suppressor
tumor-stromal cell
tumorigenesis
xenograft model

Driven by a Mission

Driven by a Mission

Driven by a Mission

Driven by a Mission

Driven by a Mission

Driven by a Mission

Driven by a Mission

Driven by a Mission

Driven by a Mission

Driven by a Mission

Sanjay Kumar Srivastava

Contact